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ABSTRACT 
Background: Policosanol is a mixture of long-chain primary aliphatic alco- 
hols purified from sugar cane wax that has cholesterol owering and antiplatelet 
effects. Omega-3 fatty acids (FA) have triglycericle lowering and antiplatelet 
effects. Combination treatment with policosanol and omega-3 FA (E~3FA) has been 
associated with significant inhibition of platelet aggregation in rabbits com- 
pared with either drug alone. 
Objective: The aim of this study was to investigate the effects of combina- 
tion treatment with E~3FA (1 g/d) and policosanol (E~3FA+Poli) compared with 
E~3FA (1 g/d) plus placebo (E~3FA+Pla) on platelet aggregation i  human patients 
with hypercholesterolemia. 
Methods: This randomized, double-blind, clinical study at the Surgical 
Medical Research Center (Havana City, Cuba) recruited outpatients from lipid 
clinics, with some atherosclerotic risk factors. Outpatients of both sexes aged 
20 to 75 years with serum total cholesterol (TC) levels >5 and <6 mmol/L were 
eligible to enroll. They were included in the study at the end of a 4-week diet sta- 
bilization period if their platelet aggregation toarachidonic acid (AA) was >50% 
and serum TC level remained >5 mmol/L. Patients were then evenly randomized 
to receive E~3FA (1 g/d) + placebo or E~3FA (1 g/d) + policosanol (10 mg/d) to be 
taken PO with the evening meal for 21 days. Treatment was assigned according 
to a randomization code using balanced blocks and a 1:1 allocation ratio. In- 
hibition of platelet aggregation toAA was the primary efficacy variable, while ef- 
fects on platelet aggregation to collagen and epinephrine and on lipid profile 
were secondary variables. Drug compliance and adverse events (AEs) were 
monitored. Tolerability was assessed using physical examinations and labora- 
tory test results. 
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Results: Sixty-four subjects were initially enrolled. Fifty-four patients (30 wom- 
en, 24 men; mean [SD] age, 58.4 [12] years, [range, 40-70 years]) met the inclusion 
criteria and were randomized to treatment; 2 groups of 27. After 21 days, platelet 
aggregation toAA was significantly inhibited in the 2 groups. E~3FA÷Poli inhibited 
platelet aggregation to all agonists by ~20%. Platelet aggregation to AA 1.0 and 
1.5 mM was inhibited with combination treatment (39.6% and 33.9%, respectively; 
both P ~ 0.001 vs baseline; P ~ 0.001 and P ~ 0.01, respectively, vs E~3FA÷Pla) nd 
with E~3FA÷Pla (11.0% and 13.3%; both, P ~ 0.001). Combination treatment was 
more effective in inhibiting platelet aggregation to AA 1.0 and 1.5 mM in 28.6% 
(P < 0.001) and 20.6% (P < 0.01), respectively. Platelet aggregation to collagen 
1 1Jg/mL was significantly inhibited with combination treatment and with E~3FA÷Pla 
compared with baseline (43.2% and 15.1%, respectively; both, P ~ 0.001), but the 
effects of combination treatment were significantly greater (P ~ 0.01). Platelet 
aggregation to epinephrine 0.1 mM was inhibited with E~3FA÷Poli and E~3FA÷Pla 
(34.8% and 20.1%; both, P ~ 0.001), with similar results for both groups. Bleeding 
time did not change significantly for either group and E~3FA÷Pla did not signifi- 
cantly change the lipid profile. Combination treatment did significantly reduce lev- 
els of low-density lipoprotein cholesterol (LDL-C) (17.4%; P < 0.001 vs baseline, P < 
0.05 vs E~3FA÷Pla) nd TC (10.1%; P < 0.001 vs baseline, P < 0.05 vs E~3FA÷Pla), 
increase high-density lipoprotein cholesterol (HDL-C) levels (18.0%; P ~ 0.001 vs 
baseline), but did not significantly change triglyceride levels. Three patients 
(2 from the E~3FA÷Poli group and 1 from the E~3FA÷Pla group) withdrew from the 
trial, though none were due to AEs. Two patients receiving combination treatment 
reported mild AEs (headache). All treatments were well tolerated. 
Conclusions: In these patients, policosanol (10 mg/d) administered concomi- 
tantly with E~3FA (1 g/d) enhanced the inhibition of platelet aggregation toAA and 
collagen, but not to epinephrine, compared with E~3FA÷Pla, without significantly 
affecting bleeding time. Concomitant treatment was also associated with reduced 
levels of LDL-C and TC and raised HDL-C levels. All treatments were well tolerated. 
(Curt Ther Res Clin Exp. 2006;67:174-192) Copyright © 2006 Excerpta Medica, Inc. 
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platelet drugs, cholesterol-lowering drugs. 
INTRODUCTION 
Coronary, cerebrovascular, nd peripheral arterial diseases are major causes of 
morbidity and mortality in adults, with atherosclerosis being the main patho- 
logic process involved in their etiology. 1,2 Hypercholesterolemia, mainly ele- 
vated serum levels of low-density lipoprotein cholesterol (LDL-C), is a major ath- 
erosclerotic risk factor. 3,4 Reducing LDL-C levels significantly prevents coronary 
events in patients with and without coronary heart disease (CHD). 5-11 Guidelines 
for preventing coronary events include achieving target LDL-C levels. 12,13 
In arterial circulation, activation of platelet aggregation is the initial event 
leading to blood clotting. Platelet aggregation is activated by several factors 
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(eg, hypercholesterolemia, hypertension, diabetes, blood turbulence), with in- 
duced functional changes in endothelial cells triggering the accumulation of
lipids and monocytes and additional platelet aggregation. 14-16 Arterial thrombi 
commonly develop along a ruptured atherosclerotic plaque or in areas of tur- 
bulent blood flow where platelets aggregate and are held by strands of fibrin. 14 
Damage to the intimal surface with denuding endothelium induces platelet 
adhesion, and the release of growth factors timulates smooth muscle cell pro- 
liferation, which leads to the development of unstable, easily ruptured lesions 
on which thrombi form. 14-18 
Therefore, decreasing platelet aggregation can reduce the risk of thrombosis 
and acute coronary syndromes (eg, myocardial infarction, sudden death, unsta- 
ble angina). The prophylactic use of antiplatelet drugs in patients at high risk of 
atherosclerosis from CHD and stroke has been clinically demonstrated, with risk 
reductions of major coronary and cerebrovascular events of 20% to 29%. 19-22 
Although a variety of antiplatelet drugs is available, aspirin remains the gold 
standard ue to its efficacy, relative safety, and low cost. 15-22 Aspirin reduces 
the coronary risk of secondary prevention patients by -25%. 19 The effects of 
aspirin on platelet aggregation are moderate, mediated only by the inhibition 
of thromboxane A 2 (TxA2) synthesis through the irreversible inhibition of 
cyclooxygenase activity, leaving platelet recruitment unaffected in other path- 
ways. 15,21 Ten percent o 20% of patients with arterial thrombosis treated with 
aspirin have experienced recurrent vascular events during long-term follow- 
up. 21 Antiplatelet drugs (eg, ticlopidine and clopidogrel) act by inhibiting the 
binding of adenosine diphosphate (ADP) to its platelet receptors without 
involving other pathways of platelet activation. 15,19-22 A limitation of currently 
available antiplatelet drugs is that none inhibits platelet aggregation against all 
agonists. 
Policosanol is a mixture of long-chain primary aliphatic alcohols purified 
from sugar cane wax (Saccharum officmarum L) that has experimentally and 
clinically demonstrated cholesterol-lowering effects. 23-32 Policosanol inhibits 
cholesterol biosynthesis through the indirect regulation of hydroxymethyl- 
glutaryl-coenzyme A reductase 33-35 by suppressing enzyme upregulation i cells 
cultured in a lipid-depleted medium through the inhibition of de novo synthesis 
and/or enzyme degradation. 35 In addition to its cholesterol-lowering effects, 
policosanol inhibits platelet aggregation 23,26,32,36,37 and LDL-C lipid peroxida- 
tion, 38,39 both of which help prevent atherosclerosis and thrombosis. Further- 
more, policosanol is well tolerated. 23-32,4°~5 Therefore, it might be useful to 
investigate he possible benefits of combination treatment with policosanol and 
other antiplatelet or lipid-modifying drugs. 
Fish oils are rich in omega-3 long-chain polyunsaturated fatty acids (FA). 46-48 
Consumption of omega-3 FA (E~3FA) is recommended for secondary coronary 
prevention, with antiarrhythmic mechanisms being the most convincing expla- 
nation for such preventive ffects. The triglyceride (TG) lowering and anti- 
platelet effects of E~-3FA could also work toward prevention. 46-52 
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Considering their effects on lipid profile and platelet function, combina- 
tion treatment with policosanol and E~3FA should be more beneficial than 
monotherapy with either drug, and some experimental nd clinical evidence 
supports this idea. 53,54 Concurrent treatment with policosanol and E~3FA sig- 
nificantly decreased levels of LDL-C, total cholesterol (TC), and TG (all, P < 
0.01) and significantly increased high-density lipoprotein cholesterol (HDL-C) 
levels in rabbits (P< 0.01); the effects of the 2 treatments were additive. 53 All 
treatments inhibited platelet aggregation to arachidonic acid (AA), but greater 
effects were achieved with policosanol + E~3FA than respective monothera- 
pies. 53 A previous clinical study demonstrated that policosanol (5 or 10 mg/d) 
administered with E~3FA (1 g/d) significantly increased the changes in LDL-C, 
TC, and HDL-C levels (all, P < 0.001), while maintaining the reduction in TG 
induced by E~3FA monotherapy. 54 Clinical studies of the effects of such com- 
bination treatment on platelet aggregation i  humans, however, have not been 
conducted (MEDLINE search through 2006, key terms: policosanol, and omega-3 
fatty acids). 
The aim of this study was to investigate whether treatment with E~3FA 
1 g/d + policosanol 10 mg/d (E~3FA+Poli) inhibits platelet aggregation more than 
E~3FA + placebo (E~3FA+Pla) inhuman patients with type II hypercholesterolemia. 
PATIENTS AND METHODS 
Study Design 
This randomized, ouble-blind study was conducted at the Surgical Medical 
Research Center (Havana City, Cuba). An independent e hics review committee 
(Ethics & Institutional Review Board, Havana City, Cuba) approved the study 
protocol. Before recruitment, each patient provided informed written consent. 
According to study protocol, outpatients of both sexes with an atherosclerotic 
risk factor (CHD, stroke or transient ischemic attack, peripheral artery disease, 
hypercholesterolemia, hypertension, diabetes, smoking, age >45 years for men, 
age >55 years for women, obesity [body mass index _>30], and/or family history 
of premature CHD) were recruited from lipid clinics and enrolled in the trial 
(visit 1). 
Patients were advised to follow a cholesterol-lowering diet for a baseline 
period of 4 weeks. 12 Thereafter, their serum lipid profile was recorded at 
weeks 4 and 5 on diet. When blood was withdrawn the second time (week 5 
on diet), aliquots were kept to determine platelet aggregation and blood 
safety. Eligible patients were included (visit 2) and randomized to E~3FA+Pla 
or E~3FA+Poli for 21 days. Patients also visited the clinic at the end of treat- 
ment (visit 3). 
The ~23FA+Pla group was included to assess whether policosanol enhanced 
the inhibition of platelet aggregation induced with E~3FA. The double-blind 
design was selected to reduce subjective bias of patients and investigators. 
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Dosage and Administration 
Eligible patients were randomized to receive E~3FA 1 g capsules + placebo or 
E~3FA 1 g capsules ÷ policosanol 10 mg. Treatments were consumed PO once a 
day with the evening meal for 21 days. E~3FA capsules were provided by Rainbow 
& Nature, Ltd. (Sydney, Australia); their content was assessed using gas chro- 
matography. They mainly contained eicosapentaenoic acid (EPA) and docosa- 
hexaenoic acid (DHEA), with other E~3FA being present at lower concentrations. 
Patients were assigned to treatment according to a randomization code using 
balanced blocks and a 1:1 allocation ratio. Patients received E~3FA in bottles 
and policosanol or placebo tablets in identical coded packages. The chosen 
close of E~3FA was low to assess the potential benefits of combination treatment 
on platelet aggregation while avoiding the risk of a potential increase in bleed- 
ing time. The close of policosanol was based on the results of a previous clini- 
cal study. 54 Because platelet half-life ranges from 7 to 10 days, 21 clays of treat- 
ment would be sufficient o explore the antiplatelet effects of the treatment. 
Enrollment Criteria 
Outpatients of both sexes aged 20 to 75 years with serum TC levels ~5 and 
~6 mmol/L were eligible to enroll in the trial. 
Inclusion Criteria 
Patients were included in the study at the end of the diet-only baseline peri- 
od if their  platelet  aggregat ion to AA was ~50% and serum TC level remained 
~5 mmol/L. 
Exclusion Criteria 
Patients were excluded at enrollment if they routinely took antiplatelet drugs 
or if they had a recurrent history of bleeding episodes indicating increased sus- 
ceptibility to hemorrhage. Patients whose bleeding time at baseline (prior to the 
second visit) was ~4 minutes were excluded from the trial as were pregnant or 
lactating women and women of childbearing potential who were not using con- 
traceptives. Patients were also excluded if they had hepatic or renal diseases, 
diagnosed neoplastic diseases, inadequately controlled hypertension (diastolic 
blood pressure ~100 mm Hg), or diabetes mellitus. Patients who had experi- 
enced any adverse event (AE) that led to hospitalization within the 3 months 
prior to the study were also excluded. 
The reasons for study withdrawals were predefined in the study protocol and 
were defined as being attributable or not to AEs. Withdrawals due to AEs included 
all discontinuations due to AEs that occurred during the trial. Bleeding time ~4 min- 
utes was predefined as a withdrawal due to an AE. Withdrawals not attributable 
to AEs included unwillingness to follow-up, travel abroad, address changes imped- 
ing attendance at planned visits, and major protocol violations (ie, no consumption 
of study drugs for ~3 consecutive clays and/or consumption of any concomitant 
drug with recognized antiplatelet, anticoagulant, or lipid-lowering effects). 
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Assessment of Compliance 
Compliance with study drug protocol was assessed by counting the tablets 
remaining at the end of the study and by patient interviews. Satisfactory compli- 
ance was defined as having taken ~85% of the scheduled tablets. Compliance 
with diet was assessed by interview and by weighing each patient. 
Patient Assessment 
At enrollment, a complete medical history was taken. Physical examinations 
were conducted at clinic visits 1, 2, and 3, and laboratory tests were done prior 
to the 3 visits. Assessment of drug compliance and AE interviews were done 
weekly. 
Efficacy Variables 
The pr imary efficacy variable was the reduction of platelet aggregation to at 
least 1 of the 2 doses of AA. Treatment was a priori and considered effective if 
the reduction in AA was significant and was ~20% compared with baseline. One 
treatment was considered more effective than the other if the final values and 
percentage changes in platelet aggregation to AA were significantly different. 
Reductions in platelet aggregation to collagen and epinephrine were consid- 
ered secondary  efficacy variables. Each treatment was considered effective if 
the reductions were significant and were ~20% versus baseline. One treatment 
was considered more effective than the other if the final values and percentage 
changes in platelet aggregation to collagen or epinephrine were significantly 
different. 
Due to the short  duration of treatment, changes in serum lipid profile vari- 
ables (LDL-C, TC, HDL-C, the ratios of LDL-C/HDL-C and TC/HDL-C) and TG 
were considered secondary  efficacy variables. Treatments were considered 
effective in lowering cholesterol  if the LDL-C level was reduced by ~15% versus 
baseline. 55 
Tolerability 
Tolerability was assessed using physical examination findings and labora- 
tory test results. Physical safety indicators included changes in weight, pulse 
rate, and arterial pressure. Laboratory tests included determination of bleeding 
time, serum alanine aminotransferase and aspartate aminotransferase activi- 
ties, and fasting serum glucose and serum creatinine levels. 
Analysis of drug tolerabil ity also included AE reports. Any undesirable xpe- 
rience occurring during the study, whether or not it was drug related, was con- 
sidered an AE; this included AEs not present at baseline and those that wors- 
ened during the study. AEs were classified as mild, moderate, or serious 
according to their intensity. An AE was considered mild if it did not require dis- 
continuation of study drug or specific treatment of the AE, and moderate if it 
required discontinuation of study drug and/or specific treatment of the AE. 
Serious AEs were those that resulted in hospitalization or death. 
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AEs were also classified according to their causal relationship to drug treat- 
ment as definite, probable, possible, or doubtful according to the Naranjo 
Adverse Drug Reaction algorithm using the following scale: doubtful = 0, possi- 
ble = 1 to 4; probable = 5 to 8; definite _>9. 56 Because only 1 previous clinical 
study had investigated the effects of the combination treatment with E~3FA+Poli, 
any AE that occurred in the study was considered related to treatment. 
Laboratory Analysis 
Venous blood samples were withdrawn after an overnight fast of 12 hours at 
weeks 4 and 5 of the baseline period, and after 21 days on treatment. 
Approximately 9 mL of venous blood was collected into tubes containing 
3.8% sodium citrate, with a final citrate/blood volume ratio of 1:9. Blood sam- 
ples were centrifuged for 10 minutes at 900 rpm, and the layer of platelet-rich 
plasma (PRP) was removed. The remaining blood sample was centrifuged for 
another 10 minutes at 3000 rpm, and the thin layer of platelet-poor plasma 
(PPP) was removed. 
Platelet aggregation responses to AA 1.0 mM, AA 1.5 mM, collagen 1 1Jg/mL, 
and epinephrine 0.1 mM were evaluated according to the light transmission 
method 57 using a dual-channel optical aggregometer (BIO/DATA Corporation, 
Horsham, Pennsylvania) calibrated for maximum light transmission; 500 1JL 
samples of PPP were used from each patient at each point. Subsequently, 
450 1JL of PRP was added to the aggregometer at 37°C for 3 minutes. The extent 
of platelet aggregation was evaluated as the percentage of maximal light trans- 
mission reached within 5 minutes of the addition of each agonist. 
TC and TG levels were determined using enzymatic reagent kits from Roche 
(Basel, Switzerland). HDL-C levels were determined from the cholesterol content 
in the supernatant obtained after [3-1ipoprotein precipitation. 58 LDL-C levels were 
calculated using the Friedewald equation. 59 Blood biochemistry safety indicators 
were determined using reagent kits (Roche). Analyses were done in a Hitachi 719 
autoanalyzer (Hitachi, Tokyo, Japan) at the Surgical Medical Research Center. 
Systematic quality control was performed throughout the study. 
Blood safety indicators were determined using reagent kits (Roche), and the 
analyses were performed using the same equipment used for the lipid profile. 
Bleeding time was determined using a routine method. Briefly, a disposable 
template was placed in the center of the ear lobule. Using the template, a lon- 
gitudinal cut of approximately 1 x 5 mm was made and the blood was gently 
blotted from near the cut without disturbing the platelet plug. The time 
required to stop the blood flow was recorded, with each value rounded to the 
nearest 15 seconds. 
Statistical Analysis 
Analyses were performed according to intent-to-treat. Data of all randomized 
patients were included in all analyses, disregarding the degree of compliance 
with treatments or if they withdrew from the trial. Sample size was calculated 
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to detect a significant relation for a 20% difference between the reduction of 
platelet aggregation toAA with E~3FA+Pla compared with E~3FA+Poli. The power 
of the test was 80%, and P < 0.05 was considered significant. A sample size of 
50 patients (25 per group) was found to be sufficient. Assuming a dropout rate 
of 5%, 53 patients needed to be included in the study. 
Baseline lipid levels were the mean of the 2 consecutive values obtained after 
the diet-only period. Considering that platelet aggregation data are commonly 
variable, within-group comparisons of continuous data were determined using 
the nonparametric Wilcoxon signed rank test for paired samples, and compari- 
sons between groups were determined using the Mann-Whitney U test. Categoric 
data were compared using the Fisher exact test. Statistical analyses were per- 
formed using Statistics for Windows release 4.2 (StatSoft, Inc., Tulsa, Oklahoma). 
RESULTS 
Baseline Characteristics 
Of the 64 patients enrolled, 54 (30 women, 24 men; mean [SD] age, 58.4 
[12] years, [range, 40-70 years]) were randomized. Ten enrolled patients were 
not included ue to platelet aggregation values to AA 1.5 mM <50% (5 patients) 
and TC level below the inclusion criterion (5 patients). Fifty-one (94.4%) of the 
randomized patients completed the trial. 
The baseline characteristics were similar in the 2 treatment groups (Table I). 
In addition to TC level >5.0 mmol/L, study patients were also associated with 
other coronary risk factors, the most frequent (>15%) being age (men >45, and 
women >55 years); arterial hypertension (18 patients, 33.3%); family history of 
premature CHD (17, 31.4%); and current smoking (9, 16.7%). The concomitant 
drugs used were also similar in the 2 groups. 
Effects of Treatment on Platelet Aggregation 
Compliance with study medication was good. With the exception of the 
3 patients who withdrew from the study (all due to protocol violations), all 
patients fulfilled the criterion of satisfactory compliance. 
Table II summarizes the effects of treatment on platelet aggregation and 
bleeding time. Baseline values were similar in the 2 treatment groups. After 
21 days of treatment, platelet aggregation toAA 1.0 and 1.5 mM was significantly 
inhibited in the 2 groups. However, a reduction from baseline in platelet aggre- 
gation to AA _>20%, the primary efficacy variable, was reached only with combi- 
nation treatment. 
Platelet aggregation to AA 1.0 and 1.5 mM was significantly inhibited with 
E~3FA+Poli (39.6% and 33.9%, respectively; both, P < 0.001 vs baseline; P < 0.001 
and P < 0.01, respectively, vs E~3FA+Pla) nd with E~3FA+Pla (11.0% and 13.3%, 
respectively; both P < 0.001 vs baseline). Combination treatment was more 
effective in inhibiting platelet aggregation to AA 1.0 and 1.5 mM in 28.6% (P < 
0.001) and 20.6% (P< 0.01), respectively. 
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Table I. Baseline demographic and clinical characteristics of study patients (N = 54).* 
~3 FA+Pla ~3 FA+Poli 
Characteristic (n = 27) (n = 27) 
Age, mean (SD), yt 58 (14) 58 (11) 
Body mass index, mean (SD), kg/m 2 26.4 (4.8) 26.1 (3.1) 
Sex, no. (%) 
Female 16 (59.3) 14 (51.9) 
Male 11 (40.7) 13 (48.1) 
Risk factors for atherosclerosis, no. (%) 
Males aged >45 years 10 (37.0) 9 (33.3) 
Females aged >55 years 10 (37.0) 9 (33.3) 
Arterial hypertension 9 (33.3) 9 (33.3) 
Current cigarette smoking 5 (18.5) 4 (14.8) 
Obesity 3 (11.1 ) 2 (7.4) 
Family history of premature CHD 11 (40.7) 6 (22.2) 
Concomitant drug use~ 
Diuretics 6 (22.2) 8 (29.6) 
ACEI 4 (14.8) 2 (7.4) 
13-Blockers 2 (7.4) 2 (7.4) 
~3FA+Pla = omega-3 fatty acids lg/d + placebo; ~3F+Poli = ~3FA lg/d + 10 mg/d policosanol; 
CHD = coronary heart disease; ACEI =angiotensin-converting enzyme inhibitors. 
*No significant between-group differences were found. 
tRange 40 to 70 years. 
~Concomitant drugs used by >2 patients/group. 
Compared with baseline, E~3FA+Poli and E~3FA+Pla significantly inhibited 
platelet aggregation to collagen (43.2% and 15.1%, respectively; both, P < 
0.001), with combination treatment being significantly more effective than 
E~3FA+Pla (P < 0.01). Likewise, E~3FA+Poli and E~3FA+Pla significantly inhibited 
platelet aggregation to epinephrine (34.8% and 20.1%, respectively; both, P < 
0.001), but the between-group differences were not significant. Therefore, the 
effects of E~3FA+Poli and E~3FA+Pla on epinephrine-induced platelet aggrega- 
tion were similar. 
The reductions in platelet aggregation to all agonists induced with 
E~3FA+Poli, including aggregation to epinephrine, were ~20%, satisfying 
the efficacy criterion. In contrast, although significant, the reductions of 
aggregation to AA and collagen with E~3FA+Pla were <20%. Therefore, com- 
bination treatment was more effective than E~3FA alone in inhibiting platelet 
aggregation. 
Bleeding times did not change significantly from baseline in either group, 
probably because of the variability in the final values. Two subjects in each 
group had final bleeding times >4 minutes. 
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Table II. Effects of omega-3 fatty acids (E~3FA) 1 g/d + placebo (E~3FA+Pla) and E~3FA 1 g/d + 
policosanol (E~3FA+Poli) 10 mg/d on platelet aggregation and bleeding time. 
Baseline, 21 Days, 
Treatment Mean (SD) Mean (SD) % Change 
Platelet aggregation 
toAA1.0 mM,% 
E~BFA+Pla 81.37 (10.29) 72.45 (15.65)* -11.0 
E23FA+Poli 76.93 (10.21) 46.44 (29.09) *t -39.6 t 
Platelet aggregation 
toAA1.5 mM,% 
E23FA+Pla 87.22 (9.12) 75.58 (1 6.59)* -1 3.3 
E23FA+Poli 84.59 (8.45) 55.94 (29.70)** -33.9 § 
Platelet aggregation 
to collagen 1 tJg/mL, % 
E23FA+Pla 78.04 (12.40) 66.23 (19.64)* -15.1 
E23FA+Poli 76.07 (10.88) 43.18 (28.88)** ~3.2 '  
Platelet aggregation 
to epinephrine 0.1 mM, % 
E23FA+Pla 78.44 (12.25) 62.65 (21.04)* -20.1 
E23FA+Poli 79.93 (12.89) 52.1 2 (29.38)* -34.8 
Bleeding time, min 
E23FA+Pla 2.25 (0.81) 2.51 (1.08) - 
E23FA+Poli 2.25 (0.73) 2.64 (1.15) - 
AA = arachidonic acid. 
*P < 0.001 versus baseline (Wilcoxon signed rank test). 
tp < 0.001 versus E23FA+Pla (Mann-Whitney U test). 
*P < 0.01 versus E23FA+Pla (Mann-Whitney U test). 
§P < 0.05 versus E23FA+Pla (Mann-Whitney U test). 
Effects of Treatment on Lipid Profile 
E~3FA+Pla did not change the lipid profile. Despite the short treatment period 
(21 days), E~3FA+Poli significantly reduced levels of LDL-C (17.4%), TC (10.1%), 
LDL-C/HDL-C (28.2%), and TC/HDL-C (21.2%) (all, P < 0.001 vs baseline and P < 
0.05 vs E~3FA+Pla) and significantly increased HDL-C (18.0%; P < 0.001 vs base- 
line), while TG levels remained unchanged (Table III). 
Tolerability 
Treatments were well tolerated. No significant changes in safety indicators 
were found (Table IV). Individual values remained within normal limits. Three 
subjects (2 from the E~3FA+Poli group, and 1 from the E~3FA+Pla group) discon- 
tinued the study, all due to protocol violations (refusal to continue treatment). 
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Table III. Effects of omega-3 fatty acids (~3FA) 1 g/d + placebo (~3FA+Pla) and ~3FA 
1 g/d + policosanol (~3FA+Poli) 10 mg/d on the lipid profile of the study patients. 
Baseline, 21 Days, 
Treatment Mean (SD) Mean (SD) % Change 
LDL-C, mmol/L 
~3FA+Pla 4.07 (0.62) 3.88 (0.73)* -4.7 
E23FA+Poli 4.02 (0.88) 3.32 (0.89) t* -1 7.4§ 
TC, mmol/L 
E23FA+Pla 5.95 (0.69) 5.80 (0.69)* -2.5 
~3FA+Poli 5.93 (0.71) 5.33 (0.76) t* -10.1 
HDL-C, mmol/L 
~3FA+Pla 1.26 (0.32) 1.35 (0.35) 7.1 
~3FA+Poli 1.28 (0.32) 1.51 (0.45)* 18.0 
TG, mmol/L 
~3FA+Pla 1.68 (0.69) 1.55 (0.67) -7.7 
~3FA+Poli 1.69 (0.66) 1.62 (0.67) -4.1 
LDL-C/HDL-C 
~3FA+Pla 3.47 (1.11) 3.15 (1.29) -9.2 
~3FA+Poli 3.37 (1.22) 2.42 (0.97)t* -28.2§ 
TC/HDL-C 
~3FA+Pla 5.02 (1.38) 4.62 (1.44) -8.0 
E~3FA+Poli 4.90 (1.30) 3.86 (1.04)t* -21.2t 
LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; 
cholesterol; TG = triglycerides. 
*P < 0.05 versus baseline (Wilcoxon signed rank test). 
tp < 0.05 versus E23FA+Pla (Mann-Whitney U test). 
*P < 0.001 versus baseline (Wilcoxon signed rank test). 
§P < 0.01 versus E23FA+Pla (Mann-Whitney U test). 
HDL-C = high-density lipoprotein 
Two pat ients,  both  t reated with E~3FA+Poli, exper ienced  mild AEs (headache)  that  
were  c lass i f ied  as poss ib ly  drug  re lated.  
DISCUSSION 
This randomized ,  doub le -b l ind ,  c l in ical  s tudy  is the  first to compare  the  effects 
of combinat ion  t reatment  with E~3FA+Poli versus  E~3FA+Pla on p la te le t  aggrega-  
t ion. The s tudy  par t i c ipants  had  serum TC levels  >5.0 mmol /L  and a var ie ty  of 
o ther  a therosc le ro t i c  r isk factors .  
Both t reatments  inh ib i ted  p la te le t  aggregat ion  to AA and co l lagen,  but  
E~3FA+Poli was  more  effect ive than  E~3FA monotherapy .  The enhancement  of 
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Table IV. Effects of omega-3 fatty acids (E~3FA) 1 g/d + placebo (E~3FA+Pla) and E~3FA 
1 g/d + policosanol (E~3FA+Poli) 10 mg/d on safety indicators of study 
patients. Values are mean (SD). 
Treatment Baseline 21 Days 
Physical safety indicator 
Weight, kg 
E~3FA+Pla 69.78 (18.14) 
E~3FA+Poli 70.39 (11.81 ) 
Pulse rate, beats/min 
E~3FA+Pla 69.44 (1.53) 
E~3FA+Poli 69.67 (1.64) 
Diastolic blood pressure, mm Hg 
E~3FA+Pla 78.89 (9.74) 
E~3FA+Poli 79.26 (6.75) 
Systolic blood pressure, mm Hg 
E~3FA+Pla 126.30 (9.67) 
E~3FA+Poli 127.04 (11.37) 
Blood safety indicator 
ALT, UI 
E~3FA+Pla 19.33 (8.66) 
E~3FA+Poli 21.56 (8.46) 
AST, Ul 
E~3FA+Pla 23.48 (7.05) 
E~3FA+Poli 22.81 (6.99) 
Serum glucose, mmol/L 
E~3FA+Pla 4.55 (0.52) 
E~3FA+Poli 4.82 (0.76) 
Serum creatinine, tJmol/L 
E~3FA+Pla 73.96 (16.47) 
E~3FA+Poli 72.93 (14.51) 
69.71 (18.28) 
70.24 (12.12) 
69.92 (2.17) 
69.40 (1.22) 
78.08 (6.34) 
Z8.80 (6.00) 
125.77 (10.65) 
124.80 (10.46) 
1 z.19 (6.95) 
17.32 (5.50) 
22.15 (8.37) 
22.44 (10.87) 
4.41 (0.61) 
4.88 (1.19) 
74.42 (16.34) 
75.52 (1 7.32) 
ALT = alanine aminotransferase; AST = aspartate aminotransferase. 
inhibition was >20% for platelet aggregation to AA, the primary efficacy vari- 
able, and to collagen. In the case of platelet aggregation to epinephrine, how- 
ever, the inhibition achieved with the combination treatment was only 14.8% 
greater than that induced with E~3FA+Pla. Therefore, we concluded that poli- 
cosanol did not enhance the inhibition of platelet aggregation to epinephrine 
induced with E~3FA monotherapy. Except for the aggregation to epinephrine, 
only the combination treatment group achieved reductions in platelet aggrega- 
tion _>20% compared with baseline values; future studies should explore the 
effect of longer treatment periods. 
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E~3FA+Pla significantly inhibited platelet aggregation to AA 1.0 and 1.5 mM 
(11.0% and 13.3%, respectively), collagen (15.1%), and epinephrine (20.1%). 
Considering that, for the purpose of the study, the treatments had to inhibit 
platelet aggregation by_>20% to be effective, this criterion was achieved for only 
epinephrine aggregation. With the addition of policosanol, platelet inhibition 
was enhanced to 39.6% (AA 1.0 mM), 33.9% (AA 1.5 mM), 43.2% (collagen), and 
34.8% (epinephrine). Therefore, combination treatment enhanced inhibition of 
platelet aggregation toAA 1.0 and 1.5 mM by 28.6% and 20.6%, respectively, over 
E~3FA+Pla treatment. Combination treatment also enhanced inhibition of platelet 
aggregation to collagen and epinephrine by 28.1% and 14.7%, respectively. 
This study was not designed to assess whether the enhancement of platelet 
inhibition with combination treatment was due to an additive or synergistic 
effect; however, the magnitude of the increases uggests that the effect was 
additive. To assess this, further studies including groups treated with poli- 
cosanol monotherapy should be conducted. 
The clinical data supporting the effects of E~3FA on platelet aggregation and 
its mediators are heterogeneous, depending on the nature and dose of the 
aggregating agent. Treatment with low doses of E~3FA induces modest 
antiplatelet ffects, while higher doses induce marked effects6°~4; the effects on 
fibrinolysis and blood coagulability are minor and inconsistent. 61 The relevance 
of the antiplatelet/antithrombotic effe ts of E~3FA to cardiovascular risk reduc- 
tion is currently being studied. 
Treatment with E~3FA inhibits platelet aggregation by counteracting the role 
of omega-6 fatty acids (E~6FA). Linoleic acid, an E~6FA supplied by a normal diet, 
is a precursor of AA. In cell membranes, linoleic acid is converted to active f~6 
eicosanoids, including thromboxanes, prostaglandins, and leukotrienes, which 
are cellular mediators of platelet aggregation and inflammation, both key pro- 
cesses in atherosclerosis and thrombosis development. 
The fact that TxA2, which is derived in platelets from AA, is a potent aggre- 
gating agent could contribute to the reduction in coronary risk induced by 
E~3FA. 5° E~3FA compete with AA, inhibiting the synthesis of TxA 2 and shifting to 
production of TxA3, a weak aggregating agent derived from EPA. The prostacy- 
clin produced in the arterial wall, which opposes the action of TxA2, is equally 
active whether it comes from AA or EPA. Therefore, the reduction of platelet 
TxA 2 appears to be relevant, at least partially, to the antiplatelet ffects of E~3FA. 
E~3FA from fish oil have been associated with significant inhibition of collagen- 
induced platelet aggregation. 6°-66 The effect of 10 g/d of fish oil is thought o be 
equivalent to that of 325 mg/d of aspirin on platelet function. 61 One hundred 
twenty subjects, 30 to 60 years old, with mildly elevated blood pressure 
and cholesterol were randomly allocated in 5 high-fat or 2 low-fat groups for 
12 weeks. The 5 high-fat groups consisted of those taking 6 fish oil capsules 
daily, 12 fish oil capsules daily, a regimen of fish, a combination of fish + fish oil, 
or placebo capsules. The 2 low-fat groups took either fish or placebo capsules. 
All groups taking E~3FA reduced platelet aggregation to collagen and platelet 
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TxB 2 responses to collagen-induced aggregation. 62 In healthy young males, a 
fish-enriched iet ÷ fish oil, but not a fish-enriched iet ÷ DHEA, significantly 
decreased platelet aggregation to collagen without altering blood coagulation 
factors. 63 Although the doses of E~3FA recommended for inhibiting platelet 
aggregation have generally been ~1 g/d, a randomized crossover study con- 
ducted in 12 healthy male volunteers uggested that a low dose of fish oil 
(350 mg/d) administered for 6 weeks reduced platelet aggregation to ADP. 64 
The effects of E~3FA on TxA 2 production have been found to be variable. An 
open study conducted in 6 healthy volunteers who supplemented their normal 
Western diet with cod liver oil for 5 months, was associated with decreased 
platelet aggregation and lowered TxA 2 levels. 65 A randomized crossover study 
suggested that oral administration of purified EPA or DHEA (6 g/d) to healthy 
volunteers did not change TxA 2 synthesis but significantly decreased platelet 
aggregation to collagen. 66 
The inhibition of platelet aggregation induced with policosanol has been 
associated with a reduction in plasma TxB2, but the association is different from 
that of E~3FA in that policosanol increases prostacyclin levels. 67,68 The molecu- 
lar mechanisms of such action are not understood, though they should not 
involve the irreversible inhibition of cyclooxygenase, because policosanol does 
not reduce prostacyclin levels. 68,69 
The results of the present study are consistent with previous findings 
because the differential effects of both E~3FA and policosanol on the vascu- 
lar production and/or release of prostacyclin could contribute to shifting the 
balance between TxB 2 and prostacyclin as occurs with combined treatment 
policosanol ÷ aspirin versus aspirin alone. 23,67,68 In addition, the enhancement of 
inhibition of platelet aggregation was only moderate, suggesting an additive 
rather than a synergistic interaction, because both policosanol and E~3FA use 
the same pathway of platelet recruitment and activation. 
Policosanol is less effective in ADP-induced platelet aggregation than in 
aggregation to AA, collagen, or epinephrine, suggesting that its action on the 
binding of ADP with its platelet receptors is small, if it occurs at all. 
Bleeding time did not change significantly in either treatment group. 
However, the lack of significance of intergroup variations could be associated 
with the high variability of posttreatment values. Further studies are needed to 
explore whether combination treatment with E~3FA÷Poli enhances bleeding 
time more than E~3FA alone. 
We did not expect significant changes in lipid profile because of the short 
duration of the study. The fact that treatment with E~3FA÷Pla did not change 
these findings, and particularly did not lower TG levels, is consistent with the 
documented effects of E~3FA on lipid profile. 5°,52 
Combination treatment with E~3FA÷Poli s gnificantly lowered levels of LDL-C 
and TC and the ratios of LDL-C/HDL-C and TC/HDL-C, while increasing HDL-C, 
supporting the hypothesis that administering policosanol with E~3FA might 
improve the lipid profile. These findings are consistent with a previous tudy of 
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the effects of E~3FA+Poli. 54However, we did not expect significant changes in 
only 21 days of treatment, because previous tudies found such changes after 
4 and 6 weeks of treatment with policosanol. 23,29 
The mean reductions in levels of TC (10.1%) and LDL-C (17.4%) in the present 
study were significant, but they were less than those obtained in the previous tudy 
(TC [15.7%] and LDL-C [26.2%]), 54 probably because of the short duration of this 
study. However, the increase in HDL-C level achieved with combination treatment 
(18.0%) was similar to that found in the previous trial (15.5%), 54 suggesting that after 
21 days the maximum effect on HDL-C had already been achieved. Nonetheless, 
because only 2 clinical studies have investigated the effects of this combination 
treatment on lipid levels, further studies, including longer-term studies, are needed. 
The fact that policosanol improves the response of LDL-C to E~3FA supports 
the potential usefulness of this combination treatment. Because LDL-C corre- 
lates well with the risk of CHD, expert guidelines indicate that cholesterol- 
lowering strategies hould set LDL-C targets based on the global risk of each 
individual patient. 12,13 The potential for a significant increase in HDL-C level is 
another advantage of using policosanol with ~'~3FA. 23 
Treatments were well tolerated, with no significant changes in the safety indi- 
cators compared with baseline. Only 3 patients discontinued the trial, none due 
to AEs. Only 2 patients, both administered combination treatment, experienced 
AEs. Both had mild headache pisodes, which were considered to be possibly 
associated with treatment. 
CONCLUSIONS 
In this study, a combination of policosanol (10 mg/d) and E~3FA (1 g/d) adminis- 
tered to adults with type II hypercholesterolemia significantly enhanced the inhi- 
bition of platelet aggregation to AA and collagen without enhancing the effect of 
E~3FA on bleeding time. The treatment also significantly decreased levels of LDL-C 
and TC and increased levels of HDL-C. All treatments were well tolerated. 
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